[1] Eckler K.  Are all estrogens created equal?[J]. Menopause, 2004, 11(1): 7-8.   doi: 10.1097/01.GME.0000103023.32049.FD
[2] Secreto G, Zumoff B.  Abnormal production of androgens in women with breast cancer[J]. Anticancer Res, 1994, 14(5B): 2113-2117.
[3] Mant C, Cason J.  Mouse mammary tumor virus and human breast cancer[J]. Cancer Res, 2005, 65(3): 1112-1113.
[4] Loman N, Johannsson O, Kristoffersson U, et al.  Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series ofearly-onseta breastcancer[J]. J Natl Cancer Inst, 2001, 93(16): 1215-1223.   doi: 10.1093/jnci/93.16.1215
[5] Brison O.  Gene amplification and tumor progression[J]. Biochim Biophys Acta, 1993, 1155(1): 25-41.
[6] Harish MG, Konda SD, MacMahon H, et al.  Breastlesions incidentally detected with CT: what the general radiologist needs to know[J]. Radi-ographics, 2007, 27(suppl1): S37-S51.
[7] 夏良, 廖翠微, 王玉锦, 等.  X线摄影和螺旋CT诊断乳腺良恶性肿瘤的评价[J]. 放射学实践, 2003, 18(6): 420-421.   doi: 10.3969/j.issn.1000-0313.2003.06.012
[8] Pediconi F, Catalano C, Roselli A, et al.  Contrast-enhanced MR mammography for evaluation of the contralateral breast in patients with diagnosed unilateral breast cancer or high-risk lesions[J]. Radiology, 2007, 243(3): 670-680.   doi: 10.1148/radiol.2433060838
[9] 尹波, 耿道颖, 刘莉.  功能磁共振成像在乳腺癌诊断中的应用[J]. 国际医学放射学杂志, 2009, 32(1): 28-32.   doi: 10.3784/j.issn.1674-1897.2009.01.Z0107
[10] 杨学伟, 杨维良, 王秀兰, 等.  99Tcm-MIBI乳腺显像与乳腺X线照相在乳腺癌诊断中的价值[J]. 中国普通外科杂志, 2004, 13(11): 801-803.   doi: 10.3969/j.issn.1005-6947.2004.11.001
[11] 陈璟, 吴华, 胡建, 等.  99Tcm-MIBI乳腺显像鉴别乳腺肿物良、恶性及探测腋窝淋巴结转移[J]. 放射学实践, 2003, 18(1): 59-61.   doi: 10.3969/j.issn.1000-0313.2003.01.022
[12] KhalkhaliI, Villanueva-MeyerJ, EdellSL, et al.  Diagnostic accuracy of 99Tcm-sestamibi breast imaging: multicenter trial results[J]. J Nucl Med, 2000, 41(12): 1973-1979.
[13] Massardo T, Alonso O, KabasakalL, et al.  Diagnostic value of 99Tcmmethylene diphosphonate and 99Tcm-pentavalent DMSA compared with 99Tcm-sestamibifor palpable breastlesions[J]. J Nucl Med, 2002, 43(7): 882-888.
[14] Lumachi F, Ferretti G, Povolato M, et al.  Axillary lymph node metastases detection with 99Tcm-sestamibi scintimammography in patients with breastcancer undergoing curative surgery[J]. Anticancer Res, 2007, 27(4C): 2949-2952.
[15] Tiling R, Stephan K, Sommer H, et al.  Tissue-specific effects on uptake of 99Tcm-sestamibi by breast lesions: a targeted analysis of false scintigraphic diagnoses[J]. J Nucl Med, 2004, 45(11): 1822-1828.
[16] AvilN, Dose J, Jänicke F, et al.  Metabolic characterization of breast tumors with position emission tomography using F-18 fluorodeoxyglucose[J]. J Clin Oncol, 1996, 14(6): 1848-1857.   doi: 10.1200/JCO.1996.14.6.1848
[17] 邹海东, 马榕, 余之刚, 等.  PET/CT诊断乳腺癌及腋窝淋巴结状态的作用评价[J]. 外科理论与实践, 2006, 11(2): 108-111.   doi: 10.3969/j.issn.1007-9610.2006.02.008
[18] Been LB, Elsinga PH, de Vries J, et al.  Positron emission tomography in patients with breast cancer using 18F-3′-deoxy-3′-fluorolthymidine(18F-FLT)—a pilot study[J]. Eur J Surg Oncol, 2006, 32(1): 39-43.   doi: 10.1016/j.ejso.2005.09.011
[19] Rhodes DJ, O'Connor MK, Phillips SW, et al.  Molecular breast imag-ing: a new technique using technetium Tc 99m scintimammography to detect small tumors of the breast[J]. Mayo Clin Proc, 2005, 80(1): 24-30.   doi: 10.1016/S0025-6196(11)62953-4
[20] Ogston KN, Miller ID, Payne S, et al.  A new histological grading system to response of breast cancer to primary chemotherapy: prognostic significance and survival[J]. Breast, 2003, 12(5): 320-327.   doi: 10.1016/S0960-9776(03)00106-1
[21] 胡军利, 向明, 王文伟, 等.  高频超声在乳腺癌新辅助化疗中的监测价值[J]. 中国医学影像技术, 2007, 23(9): 1333-1336.   doi: 10.3321/j.issn:1003-3289.2007.09.020
[22] 赵红梅, 张恒伟, 王雁.  应用彩色多普勒超声评价乳腺癌新辅助化疗前后的疗效[J]. 中国肿瘤临床与康复, 2006, 13(2): 155-156.   doi: 10.3969/j.issn.1005-8664.2006.02.019
[23] 关晏星, 雷秋模, 翟伟, 等.  99Tcm-MIBI显像评价乳腺癌新辅助化疗疗效[J]. 中华核医学杂志, 2006, 26(1): 36-38.
[24] 汪晓红, 彭卫军, 沈坤炜, 等.  fMRI监测乳腺癌新辅助化疗疗效的应用[J]. 放射学实践, 2007, 22(11): 1135-1138.   doi: 10.3969/j.issn.1000-0313.2007.11.004
[25] 张晓鹏, 李洁, 孙应实, 等.  动态增强磁共振成像对乳腺癌新辅助化疗后病理反应性的术前评价[J]. 中国医学科学院学报, 2008, 30(1): 98-103.
[26] Smith IC, Welch AE, Hutcheon AW, et al.  Positron emission tomography using 18F-fluorodeoxy-D-glucose to predictthe pathologic response of breast cancer to primary chemotherapy[J]. J Clin Oncol, 2000, 18(8): 1676-1688.   doi: 10.1200/JCO.2000.18.8.1676
[27] Rousseau C, Devillers A, Sagan C, et al.  Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography[J]. J Clin Oncol, 2006, 24(34): 5366-5372.   doi: 10.1200/JCO.2006.05.7406
[28] Emmering J, Krak NC, Van derHoeven JJ, et al.  Preoperative 18F-FDGPET after chemotherapy in locally advanced breast cancer: prognostic value as compared with histopathology[J]. Ann Oncol, 2008, 19(9): 1573-1577.   doi: 10.1093/annonc/mdn185
[29] Gennari A, Donati S, Salvadori B, et al.  Role of 2-[18F]fluorodeoxy glucose(FDG)positron emission tomography(PET)in the early assessment of response to chemotherapy in metastatic breast cancer patients[J]. Clin Breast Cancer, 2000, 1(2): 156-161.   doi: 10.3816/CBC.2000.n.014
[30] Cachin F, Prince HM, Hogg A, et al.  Powerful prognostic stratification by 18F-fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy[J]. J Clin Oncol, 2006, 24(19): 3026-3031.   doi: 10.1200/JCO.2005.04.6326
[31] Schneider JA, Divgi CR, Scott AM, et al.  Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer[J]. J Nucl Med, 1994, 35(11): 1748-1752.
[32] Stafford SE, Gralow JR, Schubert EK, et al.  Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy[J]. Acad Radiol, 2002, 9(8): 913-921.   doi: 10.1016/S1076-6332(03)80461-0